Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15652488 
Yoshimura T, et al. (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120, 137-49 15652488
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T514-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): T514‑p, CRMP‑2 iso3 (human): T619‑p, CRMP‑2 (mouse): T514‑p, CRMP‑2 (rat): T514‑p, CRMP‑2 (chicken): T514‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) transfection of inactive enzyme, transfection of wild-type enzyme

S518-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): S518‑p, CRMP‑2 iso3 (human): S623‑p, CRMP‑2 (mouse): S518‑p, CRMP‑2 (rat): S518‑p, CRMP‑2 (chicken): S518‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey

S522-p - CRMP-2 (human)
Orthologous residues
CRMP‑2 (human): S522‑p, CRMP‑2 iso3 (human): S627‑p, CRMP‑2 (mouse): S522‑p, CRMP‑2 (rat): S522‑p, CRMP‑2 (chicken): S522‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey

S473-p - Akt1 (rat)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  neuron-'brain, hippocampus'
 Cellular systems studied:  primary cultured cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BDNF increase
wortmannin BDNF inhibit treatment-induced increase
neurotrophin-3 increase
wortmannin neurotrophin-3 inhibit treatment-induced increase
NGF no change compared to control

T514-p - CRMP-2 (rat)
Orthologous residues
CRMP‑2 (human): T514‑p, CRMP‑2 iso3 (human): T619‑p, CRMP‑2 (mouse): T514‑p, CRMP‑2 (rat): T514‑p, CRMP‑2 (chicken): T514‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  neuron-'brain, hippocampus'
 Cellular systems studied:  primary cultured cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BDNF decrease
wortmannin BDNF inhibit treatment-induced decrease
neurotrophin-3 decrease
wortmannin neurotrophin-3 inhibit treatment-induced decrease
NGF no change compared to control
lithium decrease
SB216763 decrease
SB415286 decrease
olomoucine decrease
Downstream Regulation
 Effect of modification (function):  activity, inhibited, molecular association, regulation
 Effect of modification (process):  cytoskeletal reorganization
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
TUBA1B (mouse) Disrupts in vitro

S9-p - GSK3B (rat)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  neuron-'brain, hippocampus'
 Cellular systems studied:  primary cultured cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BDNF increase
wortmannin BDNF inhibit treatment-induced increase
neurotrophin-3 increase
wortmannin neurotrophin-3 inhibit treatment-induced increase
NGF no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.